Cryoport (CYRX) CSO granted stock awards and executes tax-related sale

Rhea-AI Filing Summary

Cryoport, Inc. Chief Scientific Officer Mark W. Sawicki reported a mix of equity awards and a small sale of common stock. He received 22,845 shares of common stock as restricted stock rights that vest in four equal annual installments beginning on March 14, 2027. He was also granted stock options for 68,534 shares at an exercise price of $8.60 per share, vesting 1/48 each month starting April 14, 2026, through forty-eight months.

On March 16, 2026, Sawicki sold 3,235 shares of common stock at $8.00 per share, which the company notes were required to be sold to pay taxes due upon vesting of restricted stock rights. After this tax-related sale, he directly holds 103,697 shares of Cryoport common stock, along with the newly granted stock options.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sawicki Mark W

(Last) (First) (Middle)

C/O CRYOPORT INC.

112 WESTWOOD PLACE, SUITE 350

(Street)

BRENTWOOD TN 37027

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cryoport, Inc. [ CYRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	03/14/2026		A		22,845	A	$0(1)	106,932	D
Common Stock	03/16/2026		S(2)		3,235	D	$8	103,697	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$8.6	03/14/2026		A		68,534		(3)	03/14/2033	Common Stock	68,534	$0	68,534	D

Explanation of Responses:

1. Represents restricted stock rights, which are a contingent right to receive one share of CYRX common stock, that vest in four equal annual installments beginning March 14, 2027.

2. Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights.

3. 1/48 of options vest on the 14th of each month for forty-eight months beginning April 14, 2026.

	/s/ Mark Sawicki	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Cryoport (CYRX) report for Mark W. Sawicki?

Cryoport reported that Chief Scientific Officer Mark W. Sawicki received new restricted stock rights and stock options and executed a small sale of common shares. The sale was tied to tax obligations from vesting, while the awards increase his long-term equity exposure to the company.

How many Cryoport (CYRX) shares did Mark W. Sawicki sell and at what price?

Mark W. Sawicki sold 3,235 shares of Cryoport common stock at $8.00 per share. According to the company, these shares were required to be sold to cover taxes due upon vesting of restricted stock rights, rather than representing a discretionary open-market sale.

What new stock awards did Cryoport (CYRX) grant to its Chief Scientific Officer?

Cryoport granted Mark W. Sawicki 22,845 restricted stock rights and stock options for 68,534 shares of common stock at an $8.60 exercise price. The restricted stock rights vest annually over four years, while the options vest monthly over forty-eight months starting April 14, 2026.

When do Mark W. Sawicki’s new restricted stock rights in Cryoport (CYRX) vest?

The restricted stock rights granted to Mark W. Sawicki vest in four equal annual installments beginning March 14, 2027. Each vested unit represents the right to receive one share of Cryoport common stock, aligning his incentives with the company’s long-term performance over several years.

What are the terms of Mark W. Sawicki’s new Cryoport (CYRX) stock options?

Sawicki’s stock options cover 68,534 shares of Cryoport common stock at an exercise price of $8.60 per share. One forty-eighth of the options vest on the 14th of each month for forty-eight months beginning April 14, 2026, with expiration on March 14, 2033.

How many Cryoport (CYRX) shares does Mark W. Sawicki hold after these transactions?

After the reported transactions, Mark W. Sawicki directly holds 103,697 shares of Cryoport common stock. In addition, he holds stock options covering 68,534 shares and restricted stock rights that will convert into common shares as they vest over future years.